BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)

Tip Ranks
2025.12.10 10:07

BTIG analyst Justin Zelin maintained a Hold rating on Kura Oncology, with shares closing at $10.67. Despite a consensus Strong Buy rating and a price target of $29.00, Zelin's focus remains on the Healthcare sector. His average return is 7.7% with a 38.34% success rate on stock recommendations.

BTIG analyst Justin Zelin maintained a Hold rating on Kura Oncology yesterday. The company’s shares closed yesterday at $10.67.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Zelin covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Kura Oncology, and NovaBridge Biosciences. According to TipRanks, Zelin has an average return of 7.7% and a 38.34% success rate on recommended stocks.

Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $29.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.